Screener
Syndax Pharmaceuticals SNDX Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $130,893 | $134,930 |
| Short-term investments | 221,171 | 259,140 |
| Accounts receivable | 38,116 | 37,996 |
| Inventory, net | 34,948 | 32,754 |
| Short-term deposits | 9,175 | 19,616 |
| Other receivables, net | 267 | 6,404 |
| Collaboration receivable, net | 20,507 | 23,745 |
| Prepaid expenses and other current assets | 16,100 | 13,496 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's inventories?
- Syndax Pharmaceuticals (SNDX) reported inventories of $34.95M in Q1 2026.
- How has Syndax Pharmaceuticals's inventories changed year-over-year?
- Syndax Pharmaceuticals's inventories increased by 649.3% year-over-year, from $4.66M to $34.95M.
- What does inventories mean?
- Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.
Ask your AI about Syndax Pharmaceuticals's inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude